Essa Pharma Inc. | Income Statement
Fiscal year is October-September. All values CAD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
25.30
52.50
87.70
60.60
44.30
Gross Income
25.30
52.50
87.70
60.60
44.30
SG&A Expense
1,838.70
12,521.20
24,699.20
14,215.90
14,117.20
EBIT
1,864.00
12,573.70
24,787.00
14,276.60
14,161.50
Unusual Expense
-
995.00
8,712.00
9,597.70
194
Non Operating Income/Expense
62.30
1,992.70
1,137.40
48.00
188.60
Interest Expense
35.00
-
-
1,030.70
1,170.70
Pretax Income
1,961.50
11,575.20
17,212.40
5,757.50
14,894.70
Income Tax
-
72.40
200.50
447.70
34.70
Consolidated Net Income
1,961.50
11,502.80
17,412.80
6,205.20
14,929.40
Net Income
1,961.50
11,502.80
17,412.80
6,205.20
14,929.40
Net Income After Extraordinaries
1,961.50
11,502.80
17,412.80
6,205.20
14,929.40
Net Income Available to Common
1,961.50
11,502.80
17,412.80
6,205.20
14,929.40
EPS (Basic)
2.17
12.60
12.99
4.20
3.27
Basic Shares Outstanding
903.50
917.70
1,345.20
1,454.90
4,566.50
EPS (Diluted)
2.17
12.54
12.94
4.26
3.27
Diluted Shares Outstanding
903.50
917.70
1,345.20
1,454.90
4,566.50
EBITDA
1,838.70
12,521.20
24,699.30
14,215.90
14,117.20
Non-Operating Interest Income
-
0.80
-
-
54.90
About Essa Pharma
View Profile
